Rexgenero expands manufacturing of cell-based CLI therapy REX-001
Category: #health  By Nikita Chaurasia  Date: 2019-05-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rexgenero expands manufacturing of cell-based CLI therapy REX-001

A regenerative medicine company Rexgenero, creating advanced cell-based therapies for the treatment of critical limb ischaemia, has reportedly expanded the production of its lead development therapy REX-001 by partnering with the German Red Cross Blood Donor Service in Frankfurt.

For the uninitiated, REX-001 is a novel autologous cell therapy, manufactured from the patient’s own bone marrow. The therapy is made up of immune cells namely monocytes, lymphocytes, and granulocytes along with progenitor cells used in tissue regeneration and immune modulation. The development is time critical as the fresh product has to be administered within 48 hours. The successful transfer of the manufacturing technology to the second GMP facility in Europe is the chief milestone to assure enough supply to patients participating in Rexgenero’s Phase III SALAMANDER trials in Europe to evaluate REX-001 efficacy of CLI in diabetic patients, cited sources familiar with the therapy.

Liesbeth de Jong, Rexgenero’s VP of Manufacturing and Research & Development, said in a statement that the successful transfer of the REX-001 manufacturing technology to the German Red Cross Blood Donor Service confirms the company has full control across all aspects of the manufacturing process.

REX-001 is presently being manufactured at Rexgenero-owned GMP manufacturing unit in Seville, Spain and is being used at clinical trial locations in Spain and Portugal. As per the manufacturing partnership, REX-001 will be manufactured by the German Red Cross Blood Donor Service, primarily for additional trial sites in Germany, Czech Republic, Poland, the Netherlands, Hungary, the U.K., and Austria. Nevertheless, both sites are able to produce and deliver the drug for most clinical sites within limited time, while guaranteeing manufacturing flexibility and possibilities for backup, cited credible sources.

For the record, the German Red Cross Blood Donor Service is one of Europe’s leading blood donor services. Additionally, the organization also possesses substantial expertise in GMP manufacturing of cell-based experimental medicinal products, reported sources.  

Source Credits: http://www.rexgenero.com/rexgenero-successfully-expands-manufacturing-of-rex-001-through-partnership-with-german-red-cross-blood-donor-service/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Australian researchers discover anti-parasite drug that kills COVID-19
Australian researchers discover anti-parasite drug that kills COVID-19
By Nikita Chaurasia

Researchers at Monash University, Melbourne, have reportedly announced that they discovered that an anti-parasite medicine can kill the novel strain of the coronavirus (SARS-CoV-2) that has currently brought the world to a standstill. In a study pub...

Trump calls for a $2 trillion budget for U.S. infrastructure growth
Trump calls for a $2 trillion budget for U.S. infrastructure growth
By Nikita Chaurasia

U.S. President Donald Trump has reportedly called for a $2 trillion spending budget to repair the and build new and currently crumbling infrastructure including tunnels, bridges, and roads, seizing on the COVID-19 outbreak as well as interest rates t...

Analytics 4 Life reveals new data backing novel method to predict LVEDP
Analytics 4 Life reveals new data backing novel method to predict LVEDP
By Nikita Chaurasia

Analytics 4 Life, one the leading digital health company committed to improving existing diagnostic pathways, has reportedly presented data on its heart failure research at the ACC’s (American College of Cardiology) 69th Annual Scientific Sessi...